Piramal Pharma reports earnings miss, analysts cut forecasts
after close1 source ↓written by the desknot a recommendation
- reported revenues
- ₹21b
- analyst expectations
- 4.6%
- statutory loss
- ₹1.03 per share
- by 2027
- ₹103.4b
- improvement
- 17%
Piramal Pharma reported revenues of ₹21b, falling short of analyst expectations by 4.6%. The company also posted a statutory loss of ₹1.03 per share, significantly worse than forecasts. Following this, analysts predict revenues of ₹103.4b by 2027, reflecting a 17% improvement. Earnings are expected to recover with a forecasted profit of ₹2.97 per share.
Not investment advice. For informational purposes only.